Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Essex Bio-TechnologyHKSE:01061 +0.88%86 EV-to-FCF is 4.82 as of Aug. 27, 2026, which is 75% below its 10-year median of 19.06. GuruFocus rates HKSE:01061 with a GF Score™ of 86/100 and a GF Value™ of HK$3.13 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 559 Drug Manufacturers companies, Essex Bio-Technology ranks better than 91.41% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Essex Bio-Technology's Enterprise Value is HK$824 Mil.
Essex Bio-Technology's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was HK$171 Mil. Therefore, Essex Bio-Technology's EV-to-FCF for today is 4.82.
The historical rank and industry rank for Essex Bio-Technology's EV-to-FCF or its related term are showing as below:
HKSE:01061'
s EV-to-FCF Range Over the Past 10 Years
Min: -254.66 Med: 19.06 Max: 54.61
Current: 4.96
During the past 13 years, the highest EV-to-FCF of Essex Bio-Technology was 54.61. The lowest was -254.66. And the median was 19.06.
HKSE:01061's EV-to-FCF is ranked better than 91.41% of 559
companies
in the Drug Manufacturers industry
Industry Median: 20.85
vs HKSE:01061: 4.96
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Essex Bio-Technology's PE Ratio (TTM) for today is calculated as:
Essex Bio-Technology's share price for today is HK$2.29.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Essex Bio-Technology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was HK$0.468.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Essex Bio-Technology EV-to-FCF Related Terms
Essex Bio-Technology EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Essex Bio-Technology's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Essex Bio-Technology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Essex Bio-Technology EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Essex Bio-Technology's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Essex Bio-Technology's EV-to-FCF falls into.
Essex Bio-Technology's current Enterprise Value is HK$824 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Essex Bio-Technology's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was HK$171 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Essex Bio-Technology (HKSE:01061) has a EV-to-FCF of 4.82 as of Aug. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Essex Bio-Technology and its competitors. This is 75% below median its historical median of 19.06. According to the industry distribution chart, Essex Bio-Technology ranks #48 out of 559 companies in the Drug Manufacturers industry, placing it in the top 8.6%.
Is Essex Bio-Technology's EV-to-FCF too high?
Essex Bio-Technology's current EV-to-FCF of 4.82 is 75% below median its 10-year median of 19.06. The Drug Manufacturers industry median EV-to-FCF is 20.85. Essex Bio-Technology's value of 4.82 is 76.9% below this industry median. Based on the distribution chart, Essex Bio-Technology ranks #48 out of 559 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Essex Bio-Technology has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Essex Bio-Technology's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Essex Bio-Technology ranks #48 out of 559 companies for EV-to-FCF. This places Essex Bio-Technology in the top 9% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 20.85. Essex Bio-Technology's value of 4.82 is 76.9% below this benchmark. While the company's 10-year median is 19.06 vs. the industry median of 20.85, Essex Bio-Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.85, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Essex Bio-Technology's current EV-to-FCF of 4.82 is 76.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Essex Bio-Technology and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Essex Bio-Technology's current EV-to-FCF is 4.82, which is 75% below median its own 10-year median of 19.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Essex Bio-Technology stock overvalued right now?
Based on GuruFocus' analysis, Essex Bio-Technology (HKSE:01061) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.13, compared to a current price of HK$2.29 — trading 26.8% below its estimated fair value. The current EV-to-FCF is 4.82, which is 75% below median its 10-year median of 19.06 and 76.9% below the Drug Manufacturers industry median of 20.85. Essex Bio-Technology's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Essex Bio-Technology (HKSE:01061), the current EV-to-FCF is 4.82 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Essex Bio-Technology (HKSE:01061) Overvalued in 2026?
Based on GuruFocus' analysis, Essex Bio-Technology stock appears to be undervalued.
The current stock price of HK$2.29 is trading 26.8% below its estimated GF Value™ of HK$3.13.
GuruFocus considers Essex Bio-Technology to be Modestly Undervalued.
Key valuation signals for HKSE:01061:
EV-to-FCF: 4.82 (75% below median its 10-year median of 19.06)
GF Value™: HK$3.13 vs. price of HK$2.29 (26.8% below fair value)
Industry Position: 76.9% below the Drug Manufacturers median (#48 of 559)
No single metric tells the full story. See the HKSE:01061 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture, and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, and Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel, and mouthwash. The majority of the group's revenue comes from the PRC, also operates in Hong Kong and other countries.
86GF Score
Get the complete analysis for HKSE:01061
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01061 has been successfully added to your 
